adamis pharmaceuticals corp (ADMP) Key Developments
Adamis Pharmaceuticals Corporation Files Certificate of Amendment to Amended and Restated Certificate of Incorporation
Dec 17 13
Adamis Pharmaceuticals Corporation filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, pursuant to which, effective 4:00 p.m. Eastern Standard Time on December 12, 2013, the company effected a one-for-seventeen reverse split of its issued and outstanding common stock, and reduced the number of authorized shares of common stock from 200,000,000 to 100,000,000.
Adamis Pharmaceuticals Corporation(OTCPK:ADMP) added to NASDAQ Composite Index
Dec 16 13
Adamis Pharmaceuticals Corporation will be added to NASDAQ Composite Index.
Adamis Pharmaceuticals Corporation Presents at 9th Annual Lambert, Edwards & Associates SMID-West Investor Conference, Dec-05-2013
Nov 13 13
Adamis Pharmaceuticals Corporation Presents at 9th Annual Lambert, Edwards & Associates SMID-West Investor Conference, Dec-05-2013 . Venue: The Palmer House Hilton, 17 East Monroe Street, Chicago, IL 60603, United States.
Adamis Pharmaceuticals Corporation, Annual General Meeting, Oct 15, 2013
Sep 10 13
Adamis Pharmaceuticals Corporation, Annual General Meeting, Oct 15, 2013., at 08:00 Pacific Standard Time. Location: 11455 El Camino Real, Suite 310. Agenda: To elect 5 directors to Board of Directors to serve until the next annual meeting of stockholders or until their successors have been duly elected or appointed and qualified; to consider and vote on a proposal to amend amended and restated certificate of incorporation to effect a reverse stock split of issued and outstanding common stock, if Board of Directors in its discretion determines to effect a reverse stock split, by a ratio of not less than one-for-two and not more than one-for-twenty-five at any time within 18 months after the date of the Meeting, with the exact ratio to be set at a whole number within this range as determined by the Board of Directors in its sole discretion, with a possible reduction in the number of authorized shares of common stock depending on the exact ratio of the Reverse Stock Split; to approve, on a nonbinding advisory basis, the compensation of named executive officers; and to approve executive compensation.
Adamis Pharmaceuticals Corporation Announces Positive Results of Study Concerning C31G in Treating Herpes Simplex Virus Eye Infection
Sep 9 13
Adamis Pharmaceuticals Corporation announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes Simplex Virus in an eye infection (ocular keratitis) animal model. The company previously reported that C31G successfully completed a Phase 3 contraceptive clinical trial in humans conducted by the National Institute of Child Health and Human Development. Dr. James M. Hill from Louisiana State University Health Science Center and several other investigators demonstrated that in their study C31G was effective in treating HSV in an animal model of eye infection using live rabbits. The rabbit eye model utilized for the study mimics the disease in humans. In the same study the researchers also reported that ocular administration of C31G was safe and well tolerated, confirming earlier clinical studies that established C31G safety and tolerability in other applications. The study titled The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model appears in the latest issue of the scientific journal Antiviral Research. HSV-1 is the same virus that causes cold sores and is very common in humans. It is estimated that as much as one-third of the world population suffers from various forms of recurring HSV infections. In the eye, it usually causes an infection of the cornea and that infection is the most common cause of cornea-derived blindness. Recent studies suggest that global incidence (rate of new disease) of HSV keratitis is approximately 1.5 million new cases per year including 40,000 cases of severe vision impairment or blindness. As previous animal studies have shown, C31G is also active against HSV-2, the cause of genital herpes. The company owns intellectual property relating to an antimicrobial and contraceptive product candidate called C31G. C31G is an effective spermicide and broad-spectrum antibacterial agent, which in previous studies has shown activity against both gram-positive and gram-negative organisms, including chlamydia, and a range of antibiotic resistant strains. In considering commercialization alternatives, the company intends to seek opportunities to partner the commercialization of, or license the rights to develop and commercialize, C31G with third parties that have a focus in the areas of antimicrobials or contraception.